CXChanghuo Xu

Changhuo Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Changhuo Xu has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Core–Shell Structures Govern Through-Space Interactions in Triblock Copolymers toward Deep-Red Clusteroluminescence

    by Zuping Xiong, Lidong Du, Xiong Liu, Changhuo Xu, Junlin Chen, Hanchen Shen, Longchen Zhu, Yingying Zhang, Tzu-Ming Liu, Xin Zhang, et al.

    Green fluorescent protein (GFP) and its derivatives have transformed biological imaging, yet fluorophores that simultaneously combine biocompatibility, structural programmability, and intrinsic long-wavelength luminescence remain scarce. Here, we develop a controllable one-pot polymerization strategy to construct nonconjugated triblock copolymers that can self-assemble into core–shell clusters. By modulating the hydrophilic–hydrophobic balance of copolymer chains, the core-to-shell ratio, chain packing, and electronic through-space interactions within the clusters can be precisely regulated, enabling tunable clusteroluminescence (CL) that extends to the deep-red and near-infrared emission region. Ultrafast spectroscopy further uncovers the excited-state dynamics of these core–shell clusters and reveals how the coupled evolution of electronic states and structures governs CL generation. Moreover, the core–shell clusters enable in vivo angiography under two-photon excitation, highlighting their potential as biocompatible nanofluorophores. These findings establish core–shell engineering as a general design principle for efficient clusteroluminogens, deepen the mechanistic understanding of CL, and pave the way for next-generation nanofluorescence technologies.

  • Resolving the Sensitivity–Specificity Trade‐Off in Fluorescent Probes via a Tandem‐Activatable Shielding Strategy

    by Lidong Du, Haoran Ma, Wenshan Yan, Hanchen Shen, Qingqing Zhou, Moxin Li, Manxiong Dai, Dongfeng Dang, Ruiyu Xie, Tzu‐Ming Liu, et al.

    For precise tumor diagnosis, the intrinsic trade‐off between sensitivity and specificity in fluorescent probes remains a longstanding bottleneck, underscoring an urgent need for strategies to break this fundamental constraint. To address the specificity limitation, we exploited a highly polarity‐sensitive fluorescent scaffold to construct a tandem‐activatable probe, enabling sequential activation by the acidic tumor microenvironment and the angiogenic marker aminopeptidase N. Whereas the single‐locked counterpart is prone to premature activation in circulation, the tandem‐locked probe remains inactive owing to a maleamic acid‐based shielding unit and is activated only upon encountering these two tumor hallmarks. Furthermore, this shielding strategy increases probe hydrophobicity, enhancing tumor uptake and driving accumulation of released fluorophores in low‐polarity lipid droplets, where fluorescence is markedly amplified to improve imaging sensitivity. The probe exhibits rapid and specific activation across various solid tumors with minimal toxicity, thus effectively resolving the sensitivity‐specificity trade‐off in probe design for in vivo applications.

  • Resolving the Sensitivity–Specificity Trade‐Off in Fluorescent Probes via a Tandem‐Activatable Shielding Strategy

    by Lidong Du, Haoran Ma, Wenshan Yan, Hanchen Shen, Qingqing Zhou, Moxin Li, Manxiong Dai, Dongfeng Dang, Ruiyu Xie, Tzu‐Ming Liu, et al.

    For precise tumor diagnosis, the intrinsic trade‐off between sensitivity and specificity in fluorescent probes remains a longstanding bottleneck, underscoring an urgent need for strategies to break this fundamental constraint. To address the specificity limitation, we exploited a highly polarity‐sensitive fluorescent scaffold to construct a tandem‐activatable probe, enabling sequential activation by the acidic tumor microenvironment and the angiogenic marker aminopeptidase N. Whereas the single‐locked counterpart is prone to premature activation in circulation, the tandem‐locked probe remains inactive owing to a maleamic acid‐based shielding unit and is activated only upon encountering these two tumor hallmarks. Furthermore, this shielding strategy increases probe hydrophobicity, enhancing tumor uptake and driving accumulation of released fluorophores in low‐polarity lipid droplets, where fluorescence is markedly amplified to improve imaging sensitivity. The probe exhibits rapid and specific activation across various solid tumors with minimal toxicity, thus effectively resolving the sensitivity‐specificity trade‐off in probe design for in vivo applications.

  • Harnessing Differential Restriction of Molecular Motion within a Single Fluorophore for Versatile Bioimaging

    by Xinyan Zhu, Junjun Li, Wenshan Yan, Lidong Du, Hanchen Shen, Xinwen Ou, Yingni Xu, Haoran Ma, Tzu-Ming Liu, Jacky W. Y. Lam, et al.

    Numerous studies have highlighted how differently restricted molecular motions within molecular packing can profoundly alter the photophysical properties of fluorophores. However, most investigations remain confined to solid-state luminescence polymorphism, while extending this phenomenon to biological applications remains underexplored. Here, we present a systematic study using N,N-diphenyl-4-(7-phenylbenzo[c][1,2,5]thiadiazol-4-yl) aniline-based derivant, TPABT-P, a turn-on fluorescent probe, to reveal how it can achieve versatile cellular imaging under physiological conditions by different restrictions of molecular motions. Remarkably, beyond its expected prostate-specific membrane antigen (PSMA)-specific binding activation that distinguishes PSMA-expressing cells at both cellular and in vivo levels, TPABT-P can also serve as an excellent cell membrane probe with high contrast and robust photostability. Resolving dual confinement modes can be achieved through adjustments in probe concentration or by employing fluorescence lifetime imaging. By shifting the paradigm of molecular motion confinement from solid states to dynamic living environments, this work provides a powerful insight into deciphering multidimensional fluorescence information, promising a robust toolbox for precise disease diagnostics and real-time biophysical sensing.

  • Self‐Amplifying AIE Probe for HClO‐Activatable Imaging and Antioxidative/Anti‐Inflammatory Therapy of Thoracic Aortic Dissection

    by Yanzi Xu, Yunpeng Luo, Jiale Shen, Zihao Deng, Anran Gao, Shengyi Yang, Jacky W. Y. Lam, Ryan T. K. Kwok, Changhuo Xu, Lingjie Meng, et al.

    Thoracic aortic dissection (TAD) is a highly lethal cardiovascular disease, yet its accurate diagnosis and effective treatment remain challenging due to poor imaging contrast and insufficient specificity. Leveraging the overexpressed reactive oxygen species (ROS) in TAD, we reported a hypochlorous acid (HClO)‐activatable molecular probe DT‐PZ. It enables two‐stage self‐amplifying fluorescence imaging (chemical activation and then physical aggregation) and light‐independent therapy on a single chemical entity. The probe initially exhibits quenched fluorescence via photoinduced electron transfer (PET). Two pathways can turn on the fluorescence via chemical activation: (1) oxidation by HClO blocks PET and turns on the emission; (2) photo‐triggered radicals generation of HClO (via chloride ions or myeloperoxidase) to activate neighboring probes, creating self‐amplifying fluorescence. Upon accumulation at the lesion site, the physical aggregation caused by the aggregation‐induced emission effect further amplifies the fluorescence signals. This two‐stage fluorescence amplification mechanism enables TAD visualization within 2 min in vivo. For therapy, the phenothiazine scavenges excess ROS during non‐illuminated periods, down‐regulates the NF‐κB/P65 signal pathway, and up‐regulates eNOS and P‐Akt expressions, protecting endothelial homeostasis and then improving murine survival from 50% to 90%. Collectively, DT‐PZ synergizes self‐amplifying fluorescence imaging with light‐independent antioxidation/anti‐inflammatory therapy, holding great promise for managing deep‐seated cardiovascular diseases.

  • Self‐Amplifying AIE Probe for HClO‐Activatable Imaging and Antioxidative/Anti‐Inflammatory Therapy of Thoracic Aortic Dissection

    by Yanzi Xu, Yunpeng Luo, Jiale Shen, Zihao Deng, Anran Gao, Shengyi Yang, Jacky W. Y. Lam, Ryan T. K. Kwok, Changhuo Xu, Lingjie Meng, et al.

    Thoracic aortic dissection (TAD) is a highly lethal cardiovascular disease, yet its accurate diagnosis and effective treatment remain challenging due to poor imaging contrast and insufficient specificity. Leveraging the overexpressed reactive oxygen species (ROS) in TAD, we reported a hypochlorous acid (HClO)‐activatable molecular probe DT‐PZ. It enables two‐stage self‐amplifying fluorescence imaging (chemical activation and then physical aggregation) and light‐independent therapy on a single chemical entity. The probe initially exhibits quenched fluorescence via photoinduced electron transfer (PET). Two pathways can turn on the fluorescence via chemical activation: (1) oxidation by HClO blocks PET and turns on the emission; (2) photo‐triggered radicals generation of HClO (via chloride ions or myeloperoxidase) to activate neighboring probes, creating self‐amplifying fluorescence. Upon accumulation at the lesion site, the physical aggregation caused by the aggregation‐induced emission effect further amplifies the fluorescence signals. This two‐stage fluorescence amplification mechanism enables TAD visualization within 2 min in vivo. For therapy, the phenothiazine scavenges excess ROS during non‐illuminated periods, down‐regulates the NF‐κB/P65 signal pathway, and up‐regulates eNOS and P‐Akt expressions, protecting endothelial homeostasis and then improving murine survival from 50% to 90%. Collectively, DT‐PZ synergizes self‐amplifying fluorescence imaging with light‐independent antioxidation/anti‐inflammatory therapy, holding great promise for managing deep‐seated cardiovascular diseases.

  • Open Access

    Bridging hydrogen-bond-stabilized polymeric coacervate core micelles for high-efficiency drug encapsulation and delivery

    by Jiafeng Wang, Jiajia Ying, Jianxiang Huang, Longchen Zhu, Hang Yang, JunJun Li, Zimeng Liu, Yongli Mu, Changhuo Xu, Kefeng Ding, et al.

    Polymeric nanoparticles represent one of the most promising classes of non-lipid-based drug delivery vehicles. However, their clinical translation remains limited by poor drug loading capacity and suboptimal delivery efficiency. We here develop one type of polymeric nanoparticles, referred to as PCCMs (Polymeric Coacervate Core Micelles), which are assembled from a sulfoxide-containing block polymer. Hydrophobic drugs can be efficiently encapsulated into PCCMs via a fast, low-energy "Mix-and-Go" approach, reducing reliance on organic solvents and simplifying the drug-loading process. Moreover, PCCMs show high drug loading capacities and improved stability towards versatile hydrophobic drugs. Upon evaluating 40 different drugs, 45% of the tested compounds achieve drug loading contents exceeding 40%, 80% exceed 30%, and 100% surpass 20%. Both quantitative structure-property relationship (QSPR) calculations and experimental methods identify that hydration water within PCCMs' self-coacervated cores acts as the molecular barrier, substantially inhibiting long-range-ordered drug molecule packing and stabilizing drug aggregates at the nanoscale via bridging hydrogen bonds among the polymer-water-drug. Finally, we demonstrate that PCCMs exhibit significantly higher systemic delivery efficacy compared to commercial polymeric micelle formulations in female BALB/c mice. The high loading capacity, versatility, and efficacy of PCCMs pave the way for the clinical translation of polymeric nanoparticles.


  • Twist to photoclick fast

    by Hanchen Shen, Changhuo Xu, Tzu-Ming Liu

  • Open Access

    Aggregation-induced emission of DNA fluorescence as a novel pan-marker of cell death, senescence and sepsis in vitro and in vivo

    by Yiling Hu, Xiaoyan Wang, Ke Lu, Chonin Cheang, Yichen Liu, Yaru Zhu, Liming Xie, Moxin Li, Qingqing Zhou, Wenshan Yan, et al.

    Background and Aim: Effective monitoring of cell death and senescence is critical across biology and medicine, yet a universal in situ fluorescent marker has remained elusive. This study aimed to identify and characterize a novel, endogenous optical signal arising from cellular stress and to evaluate its potential as a universal, label-free biomarker for visualizing cellular fate in diverse physiological and pathological contexts.


  • Open Access

    GSH‐Depleted Platinum(II) Metallacycles to Turn On the NIR Emission in Boosting Synergistic Cancer Therapy

    by Qifei Shen, Kai Gao, Peijuan Zhang, Xuwei Luo, Jianye Yang, Pei Zhou, Yanzi Xu, Changhuo Xu, Lingjie Meng, Heng Wang, et al.

    Agents to combine functions simultaneously are highly needed but still challenging in synergistic therapy. Particularly, capabilities to deplete glutathione (GSH) in tumors and monitor their process are also important. Therefore, platinum(II) metallacycles are prepared by using aggregation‐induced emission active ligands. Despite their similar structures, high emission for Mh1 is obtained (PLQY = 49.2%) in solids, but a PLQY of only 6.8% is recorded for Mh2. NIR emission in Mh2 can be turned‐on in depleting GSH by releasing emissive ligands. Also, both type I and type II reactive oxygen species (ROS) are obtained in Mh2 nanoparticles. Due to the depletion of GSH and generation of ROS, oxidative stress in immunogenic cell death can be induced. By combining chemotherapy and photoimmunotherapy, synergistic therapy in vivo is obtained for Mh2‐NPs to well inhibit the tumor growth, also showing antitumor immune effects in distant tumors. The work here provides some guidelines in designing the multi‐functional agents, showing the great potentials in efficient cancer therapy.